KFSHRC Successfully Treats Severe Case of 'Xanthoma' After 26 Years of Suffering

Global Healthcare Pioneer Sets New Standards in Medical Care

JEDDAH, Saudi Arabia — In an era where healthcare innovation is paramount, King Fahd Specialist Hospital and Research Centre (KFSHRC) in Jeddah has made headway in the treatment of severe Xanthoma. This milestone underscores KFSHRC's position as a trailblazer in healthcare innovation and patient care, particularly in addressing complex cases.

The Challenge of Xanthoma

Xanthoma, characterized by the accumulation of triglyceride-filled deposits beneath the skin, signals not just dermatological but deeper systemic health challenges. The condition's recurrent nature and the difficulty in finding lasting solutions have made it a focal point for KFSHRC's innovative treatment protocols.

The 26-Year Battle

A notable case involved a 58-year-old patient who, after a 26-year battle with Xanthoma and seeking treatments globally from renowned healthcare institutions, found hope in KFSHRC's bespoke treatment strategy.

The Treatment Protocol

Central to KFSHRC's successful intervention was the implementation of a modified plasma exchange technique, tailored specifically to address the unique complexities of such severe Xanthoma, particularly tackling the patient’s extreme triglyceride levels and halting the disease’s progression.

Multidisciplinary Approach

The integration of advanced apheresis technology and state-of-the-art imaging and diagnostic tools enabled the team to understand the disease and its impact thoroughly, laying the foundation for an effective treatment plan. This effort was the culmination of a multidisciplinary collaboration among nutritionists, endocrinologists, and immunohematologists, who united to formulate a holistic treatment strategy.

Published in JCEM

The treatment protocol combined dual action to mitigate the visible symptoms and address the root causes of Xanthoma. This therapeutic strategy is now published in the Journal of Clinical Endocrinology and Metabolism (JCEM), which is considered the world's leading peer-reviewed journal for endocrine clinical research and clinical practice.

Setting New Standards

Characterized by its precision and effectiveness, this technique marks a significant advancement in treatment modalities, introducing innovative ways to tackle conditions previously deemed untreatable. The comprehensive approach showcased the hospital’s adaptability and proficiency, as well as its commitment to pushing the boundaries of medical care.

Patient-Centered Care

"In addressing the patient’s challenging case of xanthoma, where multiple treatment modalities previously failed, we combined our clinical insights with an innovative application of modified plasma exchange, emphasizing our commitment to personalized healthcare," says Professor Ashraf Dada, Chairman of the Department of Pathology and Laboratory Medicine at KFSHRC in Jeddah, who led the medical care team. "This method, though less common, was chosen for its potential to precisely target the patient’s specific condition."

Impact on Patient Quality of Life

This landmark achievement not only sets new benchmarks in medical care for challenging conditions like Xanthoma but also reflects the potential of innovative treatment protocols to significantly improve patient quality of life and contribute to the scientific community.

KFSHRC's Commitment to Medical Innovation

KFSHRC's proactive engagement in medical research and innovation, alongside its dedication to sharing insights and fostering international collaborations, introduces new paradigms in the comprehension and treatment of complex diseases.

Global Recognition

KFSHRC has retained its status as the leading institution in the Middle East and Africa for the second year running and ranks 20th globally among the top 250 academic medical centers worldwide. It is also recognized as the most valuable healthcare brand in the Kingdom and the Middle East in 2024, according to Brand Finance. Additionally, Newsweek Magazine has ranked it among the top 250 hospitals globally.

Conclusion

This breakthrough not only provides hope for those with similar conditions but also places the institution at the forefront of medical innovation, highlighting its commitment to research, clinical excellence, and patient experience.

Sources

• KFSHRC Successfully Treats Severe Case of 'Xanthoma' After 26 Years of Suffering
• KFSHRC Successfully Treats Severe Case of 'Xanthoma' After 26 Years of Suffering

---

JEDDAH, Saudi Arabia — In an era where healthcare innovation is paramount, King Fahd Specialist Hospital and Research Centre (KFSHRC) in Jeddah has made headway in the treatment of severe Xanthoma. This milestone underscores KFSHRC's position as a trailblazer in healthcare innovation and patient care, particularly in addressing complex cases.

Xanthoma, characterized by the accumulation of triglyceride-filled deposits beneath the skin, signals not just dermatological but deeper systemic health challenges. The condition's recurrent nature and the difficulty in finding lasting solutions have made it a focal point for KFSHRC's innovative treatment protocols.

The 26-Year Battle

A notable case involved a 58-year-old patient who, after a 26-year battle with Xanthoma and seeking treatments globally from renowned healthcare institutions, found hope in KFSHRC's bespoke treatment strategy.

The Treatment Protocol

Central to KFSHRC's successful intervention was the implementation of a modified plasma exchange technique, tailored specifically to address the unique complexities of such severe Xanthoma, particularly tackling the patient’s extreme triglyceride levels and halting the disease’s progression.

Multidisciplinary Approach

The integration of advanced apheresis technology and state-of-the-art imaging and diagnostic tools enabled the team to understand the disease and its impact thoroughly, laying the foundation for an effective treatment plan. This effort was the culmination of a multidisciplinary collaboration among nutritionists, endocrinologists, and immunohematologists, who united to formulate a holistic treatment strategy.

Published in JCEM

The treatment protocol combined dual action to mitigate the visible symptoms and address the root causes of Xanthoma. This therapeutic strategy is now published in the Journal of Clinical Endocrinology and Metabolism (JCEM), which is considered the world's leading peer-reviewed journal for endocrine clinical research and clinical practice.

Setting New Standards

Characterized by its precision and effectiveness, this technique marks a significant advancement in treatment modalities, introducing innovative ways to tackle conditions previously deemed untreatable. The comprehensive approach showcased the hospital’s adaptability and proficiency, as well as its commitment to pushing the boundaries of medical care.

Patient-Centered Care

"In addressing the patient’s challenging case of xanthoma, where multiple treatment modalities previously failed, we combined our clinical insights with an innovative application of modified plasma exchange, emphasizing our commitment to personalized healthcare," says Professor Ashraf Dada, Chairman of the Department of Pathology and Laboratory Medicine at KFSHRC in Jeddah, who led the medical care team. "This method, though less common, was chosen for its potential to precisely target the patient’s specific condition."

Impact on Patient Quality of Life

This landmark achievement not only sets new benchmarks in medical care for challenging conditions like Xanthoma but also reflects the potential of innovative treatment protocols to significantly improve patient quality of life and contribute to the scientific community.

KFSHRC's Commitment to Medical Innovation

KFSHRC's proactive engagement in medical research and innovation, alongside its dedication to sharing insights and fostering international collaborations, introduces new paradigms in the comprehension and treatment of complex diseases.

Global Recognition

KFSHRC has retained its status as the leading institution in the Middle East and Africa for the second year running and ranks 20th globally among the top 250 academic medical centers worldwide. It is also recognized as the most valuable healthcare brand in the Kingdom and the Middle East in 2024, according to Brand Finance. Additionally, Newsweek Magazine has ranked it among the top 250 hospitals globally.

Conclusion

This breakthrough not only provides hope for those with similar conditions but also places the institution at the forefront of medical innovation, highlighting its commitment to research, clinical excellence, and patient experience.

Sources

• KFSHRC Successfully Treats Severe Case of 'Xanthoma' After 26 Years of Suffering
• KFSHRC Successfully Treats Severe Case of 'Xanthoma' After 26 Years of Suffering